Galectin Therapeutics (GALT)
Develops belapectin, a galectin-3 inhibitor, for MASH cirrhosis with portal hypertension.
Something off on this page? Send us feedback.
Develops belapectin, a carbohydrate-based inhibitor of galectin-3, for MASH cirrhosis and portal hypertension. Its clinical program is advancing toward a planned Phase 3 study, with additional development efforts in chronic liver disease and cancer.
Develops belapectin, a carbohydrate-based inhibitor of galectin-3, for MASH cirrhosis with portal hypertension. The planned Phase 3 program follows FDA feedback on its study design, primary endpoint, and regulatory framework. A global randomized, double-blind, placebo-controlled study has evaluated intravenous belapectin to prevent esophageal varices in this setting.
The development portfolio also includes research efforts in chronic liver disease and cancer. As a clinical-stage biotechnology company, operations center on clinical development. Progress toward a Phase 3 protocol depends on continued regulatory engagement, financing access, and potential strategic or financial partnership arrangements.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Dec 17, 2025 | H.C. Wainwright | Target | $11 | ||
| Dec 27, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.3M · Total debt $137.7M · Total assets $14.8M · Shareholders' equity −$136.9M
- Revenue
- $0
- Operating income
- −$4.0M
- Net income
- −$9.1M
No dividends on record.
| Institutions107 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 15.62% | 15.75M shares | |
| Insiders8 holders · as of Aug 4, 2026 | 56.27% | 56.75M shares | |
| Strategic holders1 holder · as of Dec 18, 2025 | 5.57% | 5.61M shares | |
| Otherremainder | ≈ 22.54% | 22.73M shares |
100.85M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (100.85M in the company's Sep 3, 2026 report, 65.86M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Richard E. UihleinInsiderdirector, 10 percent owner | 54.21% | 54.67M | 13Dfiled Aug 4, 2026 ↗ |
10X Fund, L.P.Strategic10 percent owner | 5.57% | 5.61M | Form 4filed Dec 18, 2025 ↗ |
BlackRock, Inc.Institution | 2.96% | 2.99M | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.15% | 2.17M | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.30% | 1.31M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 14, 2026 | Khurram Jamil | officer: Chief Medical Officer | −16,250 | $5.13 |
| Jun 29, 2026 | Khurram Jamil | officer: Chief Medical Officer | −47,467 | $5.04 |
| Jun 26, 2026 | Khurram Jamil | officer: Chief Medical Officer | −2,533 | $5.00 |
| Jun 26, 2026 | Harold H. Shlevin | director | −7,732 | $5.00 |
| Jun 29, 2026 | Harold H. Shlevin | director | −22,268 | $5.04 |
- Madrigal Pharmaceuticals
Phase 3 F4c MASH rival with oral resmetirom
- Novo Nordisk (ADR)
Phase 3 F4 MASH rival through the acquired EFX program
- Galecto
Galectin-3 rival pursuing cirrhosis with oral GB1211
- Sagimet Biosciences
F4 MASH candidate pairing denifanstat with resmetirom
- Inventiva (ADR)
Oral MASH therapy planning a compensated-cirrhosis outcomes study
- Altimmune
Late-stage GLP-1/glucagon MASH program in F2–F3 disease
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Galectin Therapeutics | $4.43 | −1.34% | $295.0M | — | — | — | — |
| Madrigal Pharmaceuticals | $546.41 | +1.43% | $12.64B | — | — | 9.8 | +71.2% |
| Novo Nordisk (ADR) | $47.46 | +1.51% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Galecto | $21.58 | −3.36% | $34.5M | — | — | — | — |
| Sagimet Biosciences | $11.56 | +5.09% | $358.1M | — | — | — | — |
| Inventiva (ADR) | $5.00 | +3.10% | $252.6M | — | — | 215.2 | — |
| Altimmune | $3.29 | +0.46% | $637.9M | — | — | 20,576.6 | +820.0% |
| Median | 11.5 | 18.9 | 112.5 | +71.2% |